Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza, Respiratory), Coagulation), Platform (Microfluidics, Immunoassays), Mode (Prescription & OTC), End-User (Hospitals, Home Care) - Global Forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1            OBJECTIVES OF THE STUDY
1.2            MARKET DEFINITION
1.2.1               MARKETS COVERED.. 24
1.2.2               YEARS CONSIDERED FOR THE STUDY
1.3            CURRENCY
1.4            LIMITATIONS
1.5            STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1            RESEARCH DATA
2.1.1               SECONDARY DATA
2.1.1.1             KEY DATA FROM SECONDARY SOURCES
2.1.2               PRIMARY DATA
2.1.2.1             KEY DATA FROM PRIMARY SOURCES
2.2            MARKET SIZE ESTIMATION
2.2.1               PRODUCT-BASED MARKET ESTIMATION
2.2.2               MARKET SIZE ESTIMATION: OVERALL POINT-OF-CARE DIAGNOSTICS MARKET
2.2.3               PRIMARY RESEARCH VALIDATION
2.3            MARKET BREAKDOWN AND DATA TRIANGULATION
2.4            RESEARCH LIMITATIONS & ASSUMPTIONS. 35
2.4.1               LIMITATIONS
2.4.2               ASSUMPTIONS

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1            POC DIAGNOSTICS MARKET OVERVIEW
4.2            POC DIAGNOSTICS MARKET SHARE, BY PRODUCT
4.3            GEOGRAPHIC SNAPSHOT OF THE POC DIAGNOSTICS MARKET

5.... MARKET OVERVIEW

5.1            INTRODUCTION
5.2            MARKET DYNAMICS
5.2.1               DRIVERS
5.2.1.1             HIGH PREVALENCE OF INFECTIOUS DISEASES IN DEVELOPING COUNTRIES
5.2.1.2             INCREASING INCIDENCE OF TARGET CONDITIONS
5.2.1.3             GROWING GOVERNMENT SUPPORT
5.2.1.4             SHORTAGE OF SKILLED LABORATORY TECHNICIANS
5.2.1.5             RISING NUMBER OF CLIA-WAIVED POC TESTS
5.2.2               RESTRAINTS
5.2.2.1             PRICING PRESSURE OWING TO REIMBURSEMENT CUTS AND BUDGET CONSTRAINTS
5.2.2.2             STRINGENT AND TIME-CONSUMING REGULATORY POLICIES
5.2.3               OPPORTUNITIES
5.2.3.1             EMERGING MARKETS
5.2.3.2             HEALTHCARE DECENTRALIZATION—CONVERTING LAB TESTS TO POC TESTS
5.2.3.3             INCREASING AWARENESS THROUGH CONFERENCES AND EVENTS
5.2.3.4             POC TESTS WITH MULTIPLEXING CAPABILITIES
5.2.4               CHALLENGES
5.2.4.1             LACK OF ALIGNMENT WITH DEFINITIVE CENTRAL LAB METHODS
5.2.4.2             INADEQUATE KNOWLEDGE ABOUT THE USE OF POC DEVICES IN PROFESSIONAL SETTINGS
5.2.4.3             RELUCTANCE TO CHANGE EXISTING DIAGNOSTIC PRACTICES
5.2.4.4             HIGH COST OF DEVICES
5.2.4.5             PRODUCT RECALLS
5.2.5               EMERGING APPLICATIONS OF POINT-OF-CARE TESTING.. 52
5.2.5.1             SEPSIS BIOMARKERS
5.2.5.2             STROKE MARKERS
5.2.5.3             THYROID TESTING
5.2.5.4             DNA TESTING
5.2.5.5             ENDOCRINE TESTING

6.... POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT

6.1            INTRODUCTION
6.2            GLUCOSE MONITORING PRODUCTS
6.2.1               GLUCOSE MONITORING PRODUCTS ACCOUNT FOR THE LARGEST SHARE OF THE POC DIAGNOSTICS MARKET
6.2.2               POINT-OF-CARE GLUCOSE MONITORING PRODUCTS MARKET SPLIT,
BY PLATFORM
6.2.3               POINT-OF-CARE GLUCOSE MONITORING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.2.4               POINT-OF-CARE GLUCOSE MONITORING PRODUCTS MARKET SPLIT,
BY END USER
6.2.5               STRIPS
6.2.6               METERS
6.2.7               LANCETS & LANCING DEVICES
6.3            CARDIOMETABOLIC MONITORING PRODUCTS
6.3.1               POINT-OF-CARE CARDIOMETABOLIC MONITORING PRODUCTS MARKET SPLIT, BY PLATFORM
6.3.2               POINT-OF-CARE CARDIOMETABOLIC MONITORING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.3.3               POINT-OF-CARE CARDIOMETABOLIC MONITORING PRODUCTS MARKET SPLIT, BY END USER
6.3.4               CARDIAC MARKER TESTING PRODUCTS
6.3.4.1             RISING GOVERNMENT INITIATIVES FOR CVD RESEARCH WILL CONTRIBUTE TO MARKET GROWTH
6.3.5               POINT-OF-CARE CARDIAC MARKER TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.3.6               POINT-OF-CARE CARDIAC MARKER TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.3.7               BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
6.3.7.1             TECHNOLOGICAL ADVANCEMENTS IN BLOOD GAS/ELECTROLYTE PRODUCTS WILL DRIVE THE GROWTH OF THIS MARKET SEGMENT
6.3.8               POINT-OF-CARE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.3.9               POINT-OF-CARE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET SPLIT, BY END USER
6.3.10             HBA1C TESTING PRODUCTS
6.3.10.1           GOVERNMENT INITIATIVES ARE PROMOTING THE REGULAR USE OF HBA1C TESTING
6.3.11             POINT-OF-CARE HBA1C TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.3.12             POINT-OF-CARE HBA1C TESTING PRODUCTS MARKET SPLIT, BY END USER
6.4            INFECTIOUS DISEASE TESTING PRODUCTS
6.4.1               POINT-OF-CARE INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
6.4.2               POINT-OF-CARE INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.4.3               POINT-OF-CARE INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY END USER
6.4.4               INFLUENZA TESTING PRODUCTS
6.4.4.1             RISING INFLUENZA PREVALENCE HAS DRIVEN THE DEMAND FOR INFLUENZA TESTING PRODUCTS
6.4.5               POINT-OF-CARE INFLUENZA TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.4.6               POINT-OF-CARE INFLUENZA TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.4.7               HIV TESTING PRODUCTS
6.4.7.1             RISING PREVALENCE OF HIV TO DRIVE MARKET GROWTH
6.4.8               POINT-OF-CARE HIV TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.4.9               POINT-OF-CARE HIV TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.4.10             HEPATITIS C TESTING PRODUCTS
6.4.10.1           CENTRAL AND EAST ASIA ARE AMONG THE HIGHLY AFFECTED REGIONS WITH HEPATITIS C
6.4.11             POINT-OF-CARE HEPATITIS C TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.4.12             POINT-OF-CARE HEPATITIS C TESTING PRODUCTS MARKET SPLIT,
BY END USER

6.4.13             SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
6.4.13.1           PRIVACY AND CONFIDENTIALITY ISSUES ARE THE KEY FACTORS LEADING TO THE ADOPTION OF POC STD TESTING PRODUCTS
6.4.14             POINT-OF-CARE STD TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.4.15             POINT-OF-CARE STD TESTING PRODUCTS MARKET SPLIT, BY END USER
6.4.16             HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
6.4.16.1           RISING PREVALENCE OF HAIS IS THE KEY FACTOR DRIVING MARKET GROWTH
6.4.17             POINT-OF-CARE HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.4.18             POINT-OF-CARE HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS MARKET SPLIT, BY END USER
6.4.19             RESPIRATORY INFECTION TESTING PRODUCTS
6.4.19.1           POCT PRODUCTS FOR THE DIAGNOSIS OF RESPIRATORY INFECTIONS OFFER LOWER SENSITIVITY AS COMPARED TO OTHER TESTS
6.4.20             POINT-OF-CARE RESPIRATORY INFECTION TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.4.21             POINT-OF-CARE RESPIRATORY INFECTION TESTING PRODUCTS MARKET SPLIT, BY END USER
6.4.22             TROPICAL DISEASE TESTING PRODUCTS
6.4.22.1           INCREASING GOVERNMENT FUNDING FOR THE USE OF POC IN TROPICAL DISEASE TESTING WILL SUPPORT MARKET GROWTH
6.4.23             POINT-OF-CARE TROPICAL DISEASE TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.4.24             POINT-OF-CARE TROPICAL DISEASE TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.4.25             OTHER INFECTIOUS DISEASE TESTING PRODUCTS
6.4.26             POINT-OF-CARE OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.4.27             POINT-OF-CARE OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET SPLIT, BY END USER
6.5            COAGULATION MONITORING PRODUCTS
6.5.1               POINT-OF-CARE COAGULATION MONITORING PRODUCTS MARKET SPLIT,
BY PLATFORM
6.5.2               POINT-OF-CARE COAGULATION MONITORING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.5.3               POINT-OF-CARE COAGULATION MONITORING PRODUCTS MARKET SPLIT,
BY END USER
6.5.4               PT/INR TESTING PRODUCTS
6.5.4.1             PT/INR IS ONE OF THE MOST COMMONLY USED COAGULATION MONITORING METHODS
6.5.5               POINT-OF-CARE PT/INR TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.5.6               POINT-OF-CARE PT/INR TESTING PRODUCTS MARKET SPLIT, BY END USER
6.5.7               ACT/APTT TESTING PRODUCTS
6.5.7.1             RISING NUMBER OF PATIENTS UNDERGOING ANGIOPLASTY AND DIALYSIS GLOBALLY TO SUPPORT MARKET GROWTH
6.5.8               POINT-OF-CARE ACT/APTT TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.5.9               POINT-OF-CARE ACT/APTT TESTING PRODUCTS MARKET SPLIT, BY END USER
6.6            PREGNANCY & FERTILITY TESTING PRODUCTS
6.6.1               POINT-OF-CARE PREGNANCY & FERTILITY TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
6.6.2               POINT-OF-CARE PREGNANCY & FERTILITY TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.6.3               POINT-OF-CARE PREGNANCY & FERTILITY TESTING PRODUCTS MARKET SPLIT, BY END USER
6.6.4               PREGNANCY TESTING PRODUCTS
6.6.4.1             RISING INCLINATION TOWARD HOME TESTING TO SUPPORT MARKET GROWTH.. 92
6.6.5               POINT-OF-CARE PREGNANCY TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.6.6               POINT-OF-CARE PREGNANCY TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.6.7               FERTILITY TESTING PRODUCTS
6.6.7.1             INCREASING AWARENESS OF FERTILITY TESTING TO DRIVE MARKET GROWTH
6.6.8               POINT-OF-CARE FERTILITY TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.6.9               POINT-OF-CARE FERTILITY TESTING PRODUCTS MARKET SPLIT, BY END USER
6.7            TUMOR/CANCER MARKER TESTING PRODUCTS. 95
6.7.1               INCREASING INVESTMENTS FOR RESEARCH RELATED TO POC CANCER TESTING ARE DRIVING MARKET GROWTH.. 95
6.7.2               POINT-OF-CARE TUMOR/CANCER MARKER TESTING PRODUCTS MARKET SPLIT, BY PLATFORM
6.7.3               POINT-OF-CARE TUMOR/CANCER MARKER TESTING PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.7.4               POINT-OF-CARE TUMOR/CANCER MARKER TESTING PRODUCTS MARKET SPLIT, BY END USER
6.8            URINALYSIS TESTING PRODUCTS
6.8.1               RISING PREVALENCE OF URINARY TRACT INFECTIONS IS DRIVING MARKET GROWTH
6.8.2               POINT-OF-CARE URINALYSIS TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM
6.8.3               POINT-OF-CARE URINALYSIS TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.8.4               POINT-OF-CARE URINALYSIS TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.9            CHOLESTEROL TESTING PRODUCTS
6.9.1               RISING OBESITY LEVELS & CARDIOVASCULAR DISORDER INCIDENCE ARE THE KEY FACTORS SUPPORTING MARKET GROWTH
6.9.2               POINT-OF-CARE CHOLESTEROL TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM
6.9.3               POINT-OF-CARE CHOLESTEROL TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.9.4               POINT-OF-CARE CHOLESTEROL TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.10          HEMATOLOGY TESTING PRODUCTS
6.10.1             PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS WILL IMPEDE MARKET GROWTH
6.10.2             POINT-OF-CARE HEMATOLOGY TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM
6.10.3             POINT-OF-CARE HEMATOLOGY TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.10.4             POINT-OF-CARE HEMATOLOGY TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.11          DRUGS-OF-ABUSE TESTING PRODUCTS
6.11.1             RISING CONSUMPTION OF ILLICIT DRUGS HAS BOOSTED DEMAND FOR TESTING
6.11.2             POINT-OF-CARE DRUGS-OF-ABUSE TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM
6.11.3             POINT-OF-CARE DRUGS-OF-ABUSE TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.11.4             POINT-OF-CARE DRUGS-OF-ABUSE TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.12          FECAL OCCULT TESTING PRODUCTS
6.12.1             LACK OF PROPER TRAINING IN THE USE OF FECAL OCCULT TESTING TO HAMPER MARKET ADOPTION
6.12.2             POINT-OF-CARE FECAL OCCULT TESTING PRODUCTS MARKET SPLIT,
BY PLATFORM
6.12.3             POINT-OF-CARE FECAL OCCULT TESTING PRODUCTS MARKET SPLIT,
BY MODE OF PURCHASE
6.12.4             POINT-OF-CARE FECAL OCCULT TESTING PRODUCTS MARKET SPLIT,
BY END USER
6.13          OTHER POC PRODUCTS
6.13.1             OTHER POC PRODUCTS MARKET SPLIT, BY PLATFORM
6.13.2             OTHER POC PRODUCTS MARKET SPLIT, BY MODE OF PURCHASE
6.13.3             OTHER POC PRODUCTS MARKET SPLIT, BY END USER

7.... POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM

7.1            INTRODUCTION
7.2            LATERAL FLOW ASSAYS
7.2.1               TECHNOLOGICAL ADVANCEMENTS AND INCREASING ADOPTION OF LFA ARE SUPPORTING MARKET GROWTH.. 112
7.3            DIPSTICKS
7.3.1               DIPSTICKS HELP IN THE ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS
7.4            MICROFLUIDICS
7.4.1               MICROFLUIDICS IS AN EMERGING PLATFORM IN POC DIAGNOSTICS
7.5            MOLECULAR DIAGNOSTICS
7.5.1               INCREASING INITIATIVES BY MARKET PLAYERS FOR DEVELOPING POC MOLECULAR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH

7.6            IMMUNOASSAYS
7.6.1               RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH

8.... POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE

8.1            INTRODUCTION
8.2            PRESCRIPTION-BASED PRODUCTS
8.2.1               GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT HAVE DRIVEN MARKET GROWTH
8.3            OTC PRODUCTS
8.3.1               RISING FOCUS ON HOME CARE IS EXPECTED TO BOOST DEMAND FOR OTC TESTING IN THE COMING YEARS

9.... POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER

9.1            INTRODUCTION
9.2            OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS
9.2.1               RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE ARE THE MAJOR FACTORS DRIVING THE GROWTH OF THIS END-USER SEGMENT
9.3            HOSPITALS/CRITICAL CARE CENTERS
9.3.1               HOSPITALS ARE AMONG THE LARGEST END USERS OF POC DIAGNOSTICS
9.4            HOME CARE SETTINGS
9.4.1               INCREASING INCLINATION TOWARDS HOME HEALTHCARE IS DRIVING THE GROWTH OF THIS END-USER SEGMENT
9.5            OTHER END USERS

10.. POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION

10.1          INTRODUCTION
10.2          NORTH AMERICA
10.2.1             US
10.2.1.1           US DOMINATED THE NORTH AMERICAN MARKET IN 2019
10.2.2             CANADA
10.2.2.1           RISING GOVERNMENT INITIATIVES TO SUPPORT THE GROWTH OF THE POC DIAGNOSTICS MARKET IN CANADA
10.3          EUROPE
10.3.1             GERMANY
10.3.1.1           GERMANY ACCOUNTED FOR THE LARGEST SHARE OF THE EUROPEAN MARKET. 138
10.3.2             FRANCE
10.3.2.1           GROWING PUBLIC-PRIVATE COLLABORATIONS FOR PRODUCT DEVELOPMENT TO DRIVE MARKET GROWTH
10.3.3             UK
10.3.3.1           GROWING AWARENESS OF THE BENEFITS OFFERED BY POC DIAGNOSTICS TO SUPPORT MARKET GROWTH IN THE UK
10.3.4             REST OF EUROPE

10.4          ASIA PACIFIC
10.4.1             JAPAN
10.4.1.1           JAPAN TO DOMINATE THE APAC POC DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
10.4.2             CHINA
10.4.2.1           RISING INVESTMENTS BY MARKET PLAYERS AND THE CHINESE GOVERNMENT TO DRIVE THE GROWTH OF THE POC DIAGNOSTICS MARKET IN CHINA
10.4.3             INDIA
10.4.3.1           HIGH BURDEN OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
10.4.4             REST OF ASIA PACIFIC
10.5          LATIN AMERICA
10.5.1             BRAZIL
10.5.1.1           RISING PREVALENCE OF DIABETES TO SUPPORT MARKET GROWTH IN BRAZIL
10.5.2             MEXICO
10.5.2.1           RISING PREVALENCE OF DIABETES AND CANCER TO SUPPORT MARKET GROWTH
IN MEXICO
10.5.3             REST OF LATIN AMERICA
10.5.4             MIDDLE EAST & AFRICA
10.5.4.1           RISING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH IN THE MEA. 158

11.. COMPETITIVE LANDSCAPE

11.1          INTRODUCTION
11.2          GLOBAL MARKET SHARE ANALYSIS, 2018
11.3          COMPETITIVE SCENARIO
11.3.1             PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
11.3.2             AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
11.3.3             ACQUISITIONS
11.4          VENDOR DIVE OVERVIEW.. 163
11.5          VENDOR INCLUSION CRITERIA
11.6          VENDOR DIVE
11.6.1             VISIONARY LEADERS
11.6.2             INNOVATORS
11.6.3             DYNAMIC DIFFERENTIATORS
11.6.4             EMERGING COMPANIES

12.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS AND SERVICES OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
12.1          ABBOTT LABORATORIES
12.2          BECTON, DICKINSON AND COMPANY
12.3          CHEMBIO DIAGNOSTICS
12.4          DANAHER CORPORATION
12.5          JOHNSON & JOHNSON
12.6          ROCHE DIAGNOSTICS (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.)
12.7          SIEMENS HEALTHINEERS GROUP
12.8          EKF DIAGNOSTICS
12.9          QUIDEL
12.10       TRINITY BIOTECH
12.11       ACCUBIOTECH
12.12       INSTRUMENTATION LABORATORY (A WERFEN COMPANY)
12.13       NOVA BIOMEDICAL
12.14       PTS DIAGNOSTICS (A PART OF SINOCARE, INC.) 207
12.15       SEKISUI DIAGNOSTICS
*BUSINESS OVERVIEW, PRODUCTS AND SERVICES OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
13.. APPENDIX

LIST OF TABLES

TABLE 1               RECENT WAIVERS FOR MARKET PRODUCTS
TABLE 2               POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 56
TABLE 3               POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 4               POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 5               POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 6               POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 7               POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 8               GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 9               GLUCOSE MONITORING METERS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 10             GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 11             POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 12             POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 13             POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 14             POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 15             POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 16             POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 17             POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 18             POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 19             POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 20             POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 21             POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 22             POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 23             POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 24             POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 25             POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 26             POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 27             POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 28             POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 29             POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 30             POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 31             POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 32             POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 33             POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 34             POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 35             POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 36             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 37             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 38             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 39             POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 40             POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 41             POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 42             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 43             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 44             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 45             POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 46             POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 47             POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 48             POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 49             POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 50             POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 51             POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 52             POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 53             POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 54             POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 55             POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 56             POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 57             POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 58             POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 59             POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 60             POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 61             POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 62             POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 63             POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 64             POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 65             POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 66             POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 67             POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 68             POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 69             POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 70             POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 71             POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 72             POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 73             POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 74             POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 75             POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 76             POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 77             POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 78             POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 79             POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 80             POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS,
BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 81             POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 82             POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 83             POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 84             POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 85             POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 86             POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 87             POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 88             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 89             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 90             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 91             POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 92             POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 93             POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 94             POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 95             POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 96             POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 97             POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 98             POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2017–2024 (USD MILLION)
TABLE 99             POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2017–2024 (USD MILLION)
TABLE 100          POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 101          POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 102          POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY END USER, 2017–2024 (USD MILLION)
TABLE 103          POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 104          POC DIAGNOSTICS MARKET, BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 105          LATERAL FLOW ASSAYS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 106          DIPSTICKS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 107          MICROFLUIDICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 108          MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 109          IMMUNOASSAYS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 110          POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2017–2024 (USD MILLION)
TABLE 111          PRESCRIPTION-BASED PRODUCTS MARKET, BY REGION,
2017–2024 (USD MILLION)
TABLE 112          OTC PRODUCTS MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 113          POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION) 123
TABLE 114          POINT-OF-CARE DIAGNOSTICS MARKET FOR OUTPATIENT HEALTHCARE & AMBULATORY CARE SETTINGS, BY REGION, 2017–2024 (USD MILLION)
TABLE 115          POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS/CRITICAL CARE CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 116          POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2017–2024 (USD MILLION)
TABLE 117          POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 118          POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION) 128
TABLE 119          NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 120          NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 121          NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2017–2024 (USD MILLION)
TABLE 122          NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 123          NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 124          US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 125          CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 126          EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 127          EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 128          EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2017–2024 (USD MILLION)
TABLE 129          EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2017–2024 (USD MILLION)
TABLE 130          EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 131          GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 132          FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 133          UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 134          ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 135          APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 136          APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 137          APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2017–2024 (USD MILLION)
TABLE 138          APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2017–2024 (USD MILLION)
TABLE 139          APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 140          JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 141          CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 142          INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 143          ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 144          LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 145          LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 146          LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2017–2024 (USD MILLION)
TABLE 147          LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2017–2024 (USD MILLION)
TABLE 148          LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2017–2024 (USD MILLION)
TABLE 149          BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 150          MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2017–2024 (USD MILLION)
TABLE 151          REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 152          MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 153          MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY PLATFORM, 2017–2024 (USD MILLION)
TABLE 154          MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2017–2024 (USD MILLION)
TABLE 155          MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY END USER, 2017–2024 (USD MILLION)

LIST OF FIGURES

FIGURE 1             RESEARCH METHODOLOGY STEPS
FIGURE 2             RESEARCH DESIGN
FIGURE 3             BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 4             RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 5             DATA TRIANGULATION
FIGURE 6             POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2019 VS. 2024 (USD MILLION)
FIGURE 7             POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2019 VS. 2024 (USD MILLION)
FIGURE 8             POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY PLATFORM, 2019 VS. 2024
FIGURE 9             POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2019 VS. 2024 (USD MILLION)
FIGURE 10          POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION
FIGURE 11          GROWING GOVERNMENT SUPPORT IS DRIVING THE ADOPTION OF POC DEVICES ACROSS THE GLOBE
FIGURE 12          GLUCOSE MONITORING PRODUCTS SEGMENT TO DOMINATE THE POC DIAGNOSTICS MARKET DURING THE FORECAST PERIOD
FIGURE 13          ASIA PACIFIC MARKET TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 14          POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES
FIGURE 15          POINT-OF-CARE DIAGNOSTICS MARKET: GROWTH FORECAST, BY REGION
(2019–2024)
FIGURE 16          NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 17          APAC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
FIGURE 18          ROCHE DIAGNOSTICS HELD THE LEADING POSITION IN THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2018
FIGURE 19          VENDOR DIVE: EVALUATION OVERVIEW
FIGURE 20          ABBOTT LABORATORIES: COMPANY SNAPSHOT
FIGURE 21          BD: COMPANY SNAPSHOT
FIGURE 22          CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT
FIGURE 23          DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 24          JOHNSON & JOHNSON: COMPANY SNAPSHOT
FIGURE 25          ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
FIGURE 26          SIEMENS HEALTHINEERS GROUP: COMPANY SNAPSHOT
FIGURE 27          EKF DIAGNOSTICS: COMPANY SNAPSHOT
FIGURE 28          QUIDEL: COMPANY SNAPSHOT
FIGURE 29          TRINITY BIOTECH: COMPANY SNAPSHOT

当レポートのプレスリリースは発行されておりません。